HBM Healthcare says Lilly to buy portfolio company Curevo Vaccine

Reuters2026/07/24 04:42

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

HBM Healthcare Investments reported a CHF 238 million Q1 FY 2026/27 profit, driven by CHF 183 million gains in listed holdings.
Private portfolio added CHF 105 million, led by Eli Lilly’s planned acquisition of Curevo Vaccine.
IPO-related gains cited for Parabilis Medicines, a USD 670 million offering, alongside Odyssey Therapeutics.
Dren Bio financing drove a CHF 71 million positive valuation effect.
New private investments: Lycia Therapeutics for USD 9 million; CellCentric for USD 12.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

HBM Healthcare says Lilly to buy portfolio company Curevo Vaccine

You may also like

Crypto prices